LNP Media Group

Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 8, 2023
Stem cell, FDA, Eli Lilly and Company, IND, Food, SCD, Trial of the century, Hematology, Biotechnology, LNP Media Group, Congress, Business development, G&A, Health, Thalassemia, Liver, Research and development, Sickle cell disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, CD34, Piz, R, Nature, Growth, Cell, Clinical trial, Gene, Partnership, LNP, PCSK9, ESGCT, AAT, Transplant, General Administration of Sport of China, AATD, Stock, GMP, Safety, European Society for Primary Immunodeficiencies, Investment, ANGPTL3, Patient, Drug discovery, Toxicity, Potential future exposure, ESCAPE, Administration, Cardiovascular disease, Pharmaceutical industry, Medical imaging, Vaccine, Lilly, Beam, Verve

CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported third quarter 2023 financial results and provided an update on the business and its clinical and pipeline progress.

Key Points: 
  • Beam anticipates that currently consented patients are sufficient to both fill the sentinel cohort (n=3) and to initiate the expansion cohort.
  • Research & Development (R&D) Expenses: R&D expenses were $100.0 million for the third quarter of 2023, compared to $85.3 million for the third quarter of 2022.
  • General & Administrative (G&A) Expenses: G&A expenses were $25.4 million for the third quarter of 2023, compared to $21.8 million for the third quarter of 2022.
  • Net Loss: Net loss was $96.1 million for the third quarter of 2023, or $1.22 per share, compared to $109.6 million for the third quarter of 2022, or $1.56 per share.

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Well, Tissue, ESCAPE, Research and development, HBF, Biotechnology, Allele, Gene editing, SCD, Clinical trial, Cancer, SMART Process Acceleration Development Environment, G&A, CD34, BCL11A, AATD, Fetal hemoglobin, CGMP, Patient, Investment, Security (finance), Administration, Cas9, Hematology, Sickle cell disease, Liver, Growth, Hospital, Trial of the century, LNP, LNP Media Group, R, Services General Administration and Coordination Department, Government of Sindh, Treatment, Safety, Pharmaceutical industry, Vaccine, Medical imaging, Television, Beam

CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported second quarter 2023 financial results and provided an update on its clinical and pipeline progress.

Key Points: 
  • Beam continues to expect initiation of current good manufacturing practice compliant operations at its North Carolina manufacturing facility in late 2023.
  • Research & Development (R&D) Expenses: R&D expenses were $97.6 million for the second quarter of 2023, compared to $74.6 million for the second quarter of 2022.
  • General & Administrative (G&A) Expenses: G&A expenses were $24.7 million for the second quarter of 2023, compared to $24.1 million for the second quarter of 2022.
  • Net Loss: Net loss was $82.8 million for the second quarter of 2023, or $1.08 per share, compared to $72.0 million for the second quarter of 2022, or $1.02 per share.

CHOP and Penn Medicine Researchers Develop "In Vivo" RNA-based Gene Editing Model for Blood Disorders

Retrieved on: 
Thursday, July 27, 2023
Nanoparticle, Bone marrow, Doctor of Philosophy, Bangladesh Technical Education Board, COVID-19 vaccine, MD, Patient, Division, Risk, Thomas, Perelman School of Medicine at the University of Pennsylvania, LNP Media Group, CD117, DSM-IV codes, Infection, Disease, Children's Hospital of Philadelphia, Tissue, Hematologic disease, BS, University, Pediatrics, Therapy, CHOP, Hematology, Gene editing, Biomedical Research, Mutation, Research, Penn Institute for Urban Research, DOI, Hospital, HSC, NIH, Vaccine, Hematopoietic stem cell, Stem cell, COVID-19, Philadelphia, Cell, Child, Antibody, Messenger, Blood, Immune system, LNP, Radiation, Doctor of Pharmacy, Cell death, PUMA, SCID, Sickle cell disease, RNA, Penn, Health, Dicarboxylic acid, Dentistry, Pharmaceutical industry, Science

PHILADELPHIA, July 27, 2023 /PRNewswire/ -- In a step forward in the development of genetic medicines, researchers at Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania have developed a proof-of-concept model for delivering gene editing tools to treat blood disorders, allowing for the modification of diseased blood cells directly within the body. If translated into the clinic, this approach could expand access and reduce the cost of gene therapies for blood disorders, many of which currently require patients receive chemotherapy and a stem cell transplant. The findings were published today in the journal Science.

Key Points: 
  • This approach could expand access and reduce the cost of gene therapies for blood disorders.
  • A targeted mRNA-encoded genomic editing methodology could lead to controlled expression, high editing efficacy, and potentially safer in vivo genomic modification compared to currently available technologies."
  • In patients with non-malignant hematopoietic disorders like sickle cell disease and immunodeficiency disorders, these blood cells don't function correctly because they carry a genetic mutation.
  • First, the researchers tested CD117/LNP encapsulating reporter mRNA to show successful in vivo mRNA expression and gene editing.

Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 10, 2023
Well, GMP, Tissue, ESCAPE, Research and development, Drug development, Stargardt disease, Hematology, Gene targeting, Biotechnology, SCD, Clinical trial, Bone marrow, Cancer, G&A, Patient, Eye, Science, AATD, Investment, Security (finance), Administration, DSM-IV codes, Sickle cell disease, Liver, R, LNP, LNP Media Group, Services General Administration and Coordination Department, Government of Sindh, Society, Vaccine, Pharmaceutical industry, Medical imaging, Stargardt, Beam

CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported first quarter 2023 financial results and provided an update on its BEACON clinical trial and pipeline progress.

Key Points: 
  • Beam expects to fully enroll the sentinel cohort in 2023.
  • Beam expects to initiate current good manufacturing practice compliant operations at its North Carolina manufacturing facility in late 2023.
  • Research & Development (R&D) Expenses: R&D expenses were $99.6 million for the first quarter of 2023, compared to $65.4 million for the first quarter of 2022.
  • General & Administrative (G&A) Expenses: G&A expenses were $23.5 million for the first quarter of 2023, compared to $19.2 million for the first quarter of 2022.

WITF and LNP | LancasterOnline Forge New Model for Local News, Community Education and Civic Engagement in Central Pennsylvania

Retrieved on: 
Wednesday, April 26, 2023
Civic, News, Journalism, Partnership, Civic engagement, Democracy, Classroom, Education, Atmosphere, Public Broadcasting Act of 1967, Politics, Culture, PBS Kids, Human, Government, Literacy, Organization, Collection, STEM, Climate, LNP, Family, LNP Media Group, PBS, Management, Road transport, Tourism, South Central Pennsylvania, WITF

HARRISBURG, Pa., April 26, 2023 /PRNewswire/ -- LNP Media Group, owned by Steinman Communications Inc., and WITF today announced that together the two organizations are forging a new model for local news, community education and civic engagement in Central Pennsylvania.

Key Points: 
  • HARRISBURG, Pa., April 26, 2023 /PRNewswire/ -- LNP Media Group, owned by Steinman Communications Inc., and WITF today announced that together the two organizations are forging a new model for local news, community education and civic engagement in Central Pennsylvania.
  • The boards of directors for WITF and Steinman Communications (LNP's parent corporation) have approved of the gift of LNP to WITF, which is expected to close in June.
  • WITF and LNP will leverage each other's strengths to achieve their educational mission through increased early childhood education, STEM education, media literacy and civic engagement programs.
  • With support from The Steinman Foundation, The Steinman Institute for Civic Engagement will advance journalism, professional development of journalists, innovation, community engagement and community-focused education initiatives.

Applied DNA Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA™ as a New Class of DNA-Based Vaccines

Retrieved on: 
Thursday, January 5, 2023
Veterinary, Research, Infectious Diseases, Genetics, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, LNP Media Group, BioRxiv, RNA transfection, Cornell University College of Veterinary Medicine, Applied Biosystems, DNA, Polymerase chain reaction, Dog, CDMO, CAR, Severe acute respiratory syndrome coronavirus 2, Veterinary medicine, Safety, Therapy, Applied DNA Sciences, Manuscript, Vaccine, PCR, LNP

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced the publication of a peer-reviewed research article in Molecular Therapy – Methods & Clinical Development .

Key Points: 
  • Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced the publication of a peer-reviewed research article in Molecular Therapy – Methods & Clinical Development .
  • An initial manuscript detailing the study’s findings was published in preprint form on bioRxiv in July 2022.
  • The study demonstrated safety and immunogenicity of a linearDNA vaccine candidate against SARS-CoV-2 in a cohort of family-owned felines.
  • Prime-boost vaccinations were administered by electro-gene-transfer intramuscularly to the cohort, which induced robust neutralizing antibody titers and cellular immune responses.

Applied DNA Biotherapeutics Subsidiary Reports LinearDNA™ Platform Development Milestone: First Successful Administration of LinearDNA In Vivo via Lipid Nanoparticles (LNP)

Retrieved on: 
Wednesday, August 10, 2022
Research, Genetics, Biotechnology, Biometrics, Health, Pharmaceutical, General Health, Other Science, Science, FDA, LNP Media Group, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Drug Quality and Security Act, EP, Mouse, IM, CEO, Forward-looking statement, Private Securities Litigation Reform Act, Applied DNA Sciences, SEC, Securities Exchange Act of 1934, Leadership, CD123, Research, History, Annual report, Lymphoma, Electroporation, DNA, Cell, USDA, Company, COVID-19, Twitter, Therapy, Biotechnology, Polymerase chain reaction, NASDAQ, LNP, Securities Act of 1933, United States Department of State, United States Department of Agriculture, PCR, Severe acute respiratory syndrome coronavirus 2, LinkedIn, Food, RNA transfection, Vaccine

Using similar LNP technology, LineaRx has achieved expression in mice of a linearDNA-LNP construct encoding reporter proteins via simple IM injection.

Key Points: 
  • Using similar LNP technology, LineaRx has achieved expression in mice of a linearDNA-LNP construct encoding reporter proteins via simple IM injection.
  • The linearDNA-LNP construct used in the successful study was developed and manufactured by Applied DNA.
  • LineaRx is developing and commercializing the LinearDNA platform as a cell-free enzymatic platform for the large-scale DNA manufacture of high-fidelity DNA sequences for use in nucleic acid-based therapeutics.
  • Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA").

Omega Therapeutics Announces FDA Clearance of IND Application for OTX-2002, First Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma

Retrieved on: 
Thursday, July 14, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Technology, Disease, SEC, Clinical trial, LNP, Gene expression, Program, Vaccine, IND, OEC, Hair, Hepatocellular carcinoma, Therapy, MYC, Patient, HCC, OMEGA, Food, COVID-19, Cell death, Risk, Private Securities Litigation Reform Act, Time, RNA transfection, Trial of the century, LNP Media Group, Investment, Nasdaq, Regenerative medicine, FDA, Research, Growth, Flagship Pioneering, Omega, Pharmaceutical industry

OTX-2002, an Omega Epigenomic Controller (OEC), is designed to downregulate c-Myc (MYC) expression pre-transcriptionally through epigenetic modulation while potentially overcoming MYC autoregulation.

Key Points: 
  • OTX-2002, an Omega Epigenomic Controller (OEC), is designed to downregulate c-Myc (MYC) expression pre-transcriptionally through epigenetic modulation while potentially overcoming MYC autoregulation.
  • "This is an important milestone for our company, representing our first program to receive FDA clearance to enter the clinic and the first ever clinical trial to evaluate an epigenomic controller.
  • This new class of programmable mRNA therapeutics leverages our groundbreaking science and has broad potential applicability in many therapeutic areas."
  • OTX-2002 is a first-in-class Omega Epigenomic Controller in development for the treatment of HCC.

Omega Therapeutics to Present New Preclinical Data for the First Epigenomic Controller, OTX-2002, for Hepatocellular Carcinoma at the European Society of Medical Oncology's 2022 World Congress on Gastrointestinal Cancer

Retrieved on: 
Thursday, June 23, 2022
Time, FDA, Risk, COVID-19, HCC, Therapy, Poster, Hair, MYC, Technology, Vaccine, Regenerative medicine, ESMO, Gene expression, European Society for Medical Oncology, Company, Omega, Flagship Pioneering, Research, Private Securities Litigation Reform Act, Growth, Congress, Disease, OEC, OMEGA, Investment, LNP Media Group, IND, SEC, Hepatocellular carcinoma, Nasdaq, LNP, Patient, Cell death, RNA transfection

OTX-2002 is a first-in-class Omega Epigenomic Controller in development for the treatment of HCC.

Key Points: 
  • OTX-2002 is a first-in-class Omega Epigenomic Controller in development for the treatment of HCC.
  • OTX-2002 is an mRNA therapeutic delivered via lipid nanoparticles (LNPs) and is designed to downregulate c-Myc (MYC) expression pre-transcriptionally through epigenetic modulation while potentially overcoming MYC autoregulation.
  • The MYC oncogene is associated with aggressive disease in up to ~70% of patients with HCC.
  • An IND application for OTX-2002 for the treatment of HCC has been submitted to the FDA.

Beam Therapeutics Reports Pipeline and Business Highlights, Planned 2022 Milestones and Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Monday, February 28, 2022
Cell, Security (finance), CAR, COVID-19, Annual general meeting, Therapy, Transplant, IND, SCD, Liver, R, Nasdaq, Society for Immunotherapy of Cancer, Private Securities Litigation Reform Act, Research, Society, Gene, Hematology, Initiate, U.S. Securities and Exchange Commission, Biotechnology, Sickle cell disease, Program, Rare, Gene editing, Neoplasm, Administration, Immunotherapy, LNP, G&A, DNA, SITC, HSC, Patient, GLOBE, Central nervous system, Potential, Toxicity, Research and development, Annual report, LNP Media Group, CD5, ASH, Acquisition, Magenta, BioScience Research Collaborative, Health, Glycogen storage disease, Busulfan, Degenerative disease, Technology, General Administration of Sport of China, Patent, Standard of care, Pharmaceutical industry, Vaccine, Medical imaging, Animal, Lithium, Pfizer, Beam

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced pipeline and business highlights, outlined key 2022 anticipated milestones and reported fourth quarter and full year 2021 financial results.

Key Points: 
  • This is an exciting time for Beam, and Im optimistic about the year ahead as we work to bring potentially life-changing medicines to patients.
  • The collaboration has an initial term of four years and may be extended up to one additional year.
  • This approach could provide a more accessible option for patients, particularly in regions where ex vivo treatment is challenging.
  • Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines.